Business Context and Reporting Period
This Form 8-K is filed by Angion Biomedica Corp. (ANGN) on April 27, 2023. The report discloses two primary events: the status of a proposed merger with Elicio Therapeutics, Inc. and a clinical milestone achieved by Elicio.
Merger Status
On January 17, 2023, Angion entered into a Merger Agreement to acquire Elicio Therapeutics, a clinical-stage biotechnology company developing immunotherapies. Upon completion, Elicio will become a wholly owned subsidiary of Angion.
Clinical Milestone
On April 27, 2023, Elicio announced the dosing of the first patient in its Phase 1/2 Study of ELI-002 7P (AMPLIFY-7P). The study targets KRAS/NRAS mutated solid tumors and is being conducted at Northwell Health Cancer Institute and the Feinstein Institutes for Medical Research in New York.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data for either Angion or Elicio. The document is a current report regarding specific corporate events rather than a periodic financial report.
Material Changes
The filing reports the following material developments:
- Merger Progress: Confirmation of the ongoing merger process between Angion and Elicio, with a Form S-4 registration statement previously filed.
- Operational Update: Initiation of the AMPLIFY-7P clinical trial with the first patient dosed, marking a key development stage for Elicio's proprietary Amphiphile technology.
Guidance, Outlook, and Risks
Management Commentary: The filing directs investors to the Form S-4 registration statement and proxy statement/prospectus for detailed information regarding the merger terms and the companies' outlook.
Risks and Contingencies: The merger is subject to the satisfaction of conditions described in the Merger Agreement. The filing explicitly states that this communication does not constitute an offer to sell or a solicitation of an offer to buy securities.
Key Facts for Investor Verification
- Verify the terms and conditions of the merger by reviewing the Form S-4 filed by Angion on February 13, 2023.
- Confirm the status of the AMPLIFY-7P Phase 1/2 study and the specific inclusion criteria for KRAS/NRAS mutated solid tumors.
- Review the proxy statement/prospectus for details on the exchange ratio and voting requirements for the merger.
- Check for any subsequent filings regarding the approval or termination of the Merger Agreement.